ROIVANT SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.03 USD | +1.38% |
|
+5.45% | -1.78% |
| 04-05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| 04-04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
| Sales 2024 * | 655M 52.21B | Sales 2025 * | 169M 13.47B | Capitalization | 8.89B 709B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.25B 339B | Net income 2025 * | -998M -79.6B | EV / Sales 2024 * | 3.95 x |
| Net cash position 2024 * | 6.3B 503B | Net cash position 2025 * | 5.11B 407B | EV / Sales 2025 * | 22.4 x |
| P/E ratio 2024 * |
2.13
x | P/E ratio 2025 * |
-8.54
x | Employees | 904 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roivant Sciences Ltd.
More recommendations
More press releases
More news
| 1 day | +1.38% | ||
| 1 week | +5.45% | ||
| Current month | +4.65% | ||
| 1 month | +4.65% | ||
| 3 months | +6.36% | ||
| 6 months | +31.62% | ||
| Current year | -1.78% |
1 week
10.51
11.11
1 month
10.1511.80
Current year
9.6912.00
1 year
8.0613.24
3 years
2.5216.76
5 years
2.5216.76
10 years
2.5216.76
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 29/02/16 |
Richard Pulik
DFI | Director of Finance/CFO | - | 27/09/21 |
Eric Venker
PSD | President | 37 | 31/12/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 12/03/23 | |
Keith Manchester
BRD | Director/Board Member | 55 | 31/12/13 |
Dan Gold
BRD | Director/Board Member | 56 | 31/12/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.81% | 4 M€ | +20.15% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 11.03 | +1.38% | 3,109,700 |
| 25/04/24 | 10.88 | -0.18% | 3,719,731 |
| 24/04/24 | 10.9 | -0.37% | 2,837,387 |
| 23/04/24 | 10.94 | +3.21% | 4,978,898 |
| 22/04/24 | 10.6 | +1.34% | 5,323,946 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohnâs disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Sector
Pharmaceuticals
Calendar
25/06/2024
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
11.03
USD
Average target price
16.08
USD
Spread / Average Target
+45.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.78% | 8.89B | |
| +25.83% | 661B | |
| +26.07% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.55% | 231B | |
| +5.31% | 200B | |
| -9.04% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ROIV Stock
